Protein Sciences Announces Completion of Targeted Enrollment of Subjects in a Phase II/III Clinical Trial of FluBlok(TM), its Patented Cell Culture Influenza Vaccine
MERIDEN, Conn., Nov. 22 /PRNewswire/ -- Protein Sciences Corporation, a world leader in developing the next generation of safer, more effective human and veterinary vaccines, announced today that it completed enrollment of 460 subjects in a Phase II/III proof of principle/field study of FluBlok(TM), its patented cell culture influenza vaccine. The study is comparing two different doses of FluBlok to a placebo group. The study sites are the University of Rochester, NY (Dr. John Treanor, Study Principal Investigator), the University of Cincinnati Children's Hospital (Dr. Gilbert Schiff) and the University of Virginia (Dr. Frederick Hayden). Daniel D. Adams, President and CEO of Protein Sciences stated, "We believe that as enrolled the trial we will not only achieve our primary endpoint -- showing safety and establishing a commercial dose for FluBlok -- but also will show by statistically significant data that FluBlok protects against influenza under field conditions as well or better than licensed vaccines." About Protein Sciences. Founded in 1983, Protein Sciences is a vaccine company focused primarily on using modern technology to make the next generation of safer and more effective human and animal vaccines. The Company has a pipeline of patented products that includes two influenza vaccines that have completed Phase II(b) human clinical trials, one of which, FluBlok, is in Phase II/III trials, and a SARS vaccine and erythropoietin that have completed animal tests and will enter human testing soon. All products are recombinant proteins that are made using the Company's patented protein expression technology, the baculovirus protein expression system (BEVS), in which it is the world leader. Protein Sciences also has a service business that is driven by its BEVS technology including GeneXpress(R) (developing and manufacturing vaccines, therapeutics and diagnostics for customers) and manufacturing and selling proteins related to HIV/AIDS, SARS, influenza and pandemic influenza for research use. The Company has developed all of its products and businesses internally and retains commercial rights to its major products. Its facilities are located in Meriden, CT and include offices, research and development laboratories and a cGMP pilot plant capable of manufacturing clinical materials at the 600-Liter scale. Website: http://www.proteinsciences.com.
SOURCE Protein Sciences Corporation
More by this Source
Flublok® Influenza Vaccine Now Available!
Nov 13, 2013, 16:01 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.